Typhoid Vi polysaccharide vaccine

DB10803ApprovedInvestigationalVaccinesInactivated Salmonella Typhi Vaccine

Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for... The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain.

First approval
Canada, 2001 · United States, 1994
Also known as
Salmonella typhi TY2 Vi polysaccharide antigen · Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Brand names
  • Typhim Vi

Resolves to

Compound
UNII7194H8W3KT
Clinical / RWD
RxNorm807219ATCJ07AP03

What you can answer from here — as of May 03, 2025

289Drug interactionsStructured to mechanism, not free text
Sign in
35Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
20Marketed productsAcross 9 countries and 9 labellers
Sign in
1ATC codeIncluding every combination product, plus 6 drug categories
Sign in

Which other approved drugs treat the same conditions as Typhoid Vi polysaccharide vaccine, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In